IPR / Market Protection

Targovax owns a broad patent portfolio which is designed to protect its pipeline and includes different families of patents and patent applications covering product candidates in development, and relevant combination therapies. This patent portfolio also covers potential future product candidates. The Company continuously works to strengthen its patent portfolio.

The Company has attained Orphan Drug Designation (ODD) in the EU and US for the use of ONCOS-102 in mesothelioma, ovarian cancer, and soft tissue sarcoma, ensuring up to 10 years of market protection from the date of market approval in any of these indications. The use of TG01 in pancreatic cancer has been granted ODD in the EU and US. In November 2016, Targovax was granted a European patent for ONCOS-102, following the award of a similar US patent in June 2016. These patents expire in 2029.

In September 2017, Targovax was granted a US patent for its mutRAS neo-antigen platform that protects the therapeutic cancer vaccine candidates TG01 and TG02 for the treatment of cancer in combination with anti-metabolite chemotherapy. This patent expires in 2035. US and European patents were granted in October 2017 and June 2018 respectively that protects Targovax's mutRAS specific neo-antigen vaccine candidate TG02 as a composition of matter to stimulate the immune system of cancer patients with RAS-mutated tumors. These patents expire in 2034 and 2033, respectively.